Abstract
Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme. Although generally well tolerated, haematological side effects are observed in approximately 1-10% of patients receiving TMZ. We report a case of a patient who developed severe bone marrow failure (BMF) after only 3 weeks of concomitant TMZ. The BMF was grave with no signs of improvement for 12 months, resulting in more than 100 transfusions of blood cells.
2016 BMJ Publishing Group Ltd.
MeSH terms
-
Aged
-
Anemia, Aplastic / chemically induced*
-
Anemia, Aplastic / drug therapy
-
Bone Marrow Diseases / chemically induced*
-
Bone Marrow Diseases / drug therapy
-
Bone Marrow Failure Disorders
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / surgery
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Fatal Outcome
-
Filgrastim / administration & dosage
-
Filgrastim / therapeutic use
-
Glioblastoma / drug therapy*
-
Glioblastoma / surgery
-
Hemoglobinuria, Paroxysmal / chemically induced*
-
Hemoglobinuria, Paroxysmal / drug therapy
-
Humans
-
Male
-
Receptors, Fc / administration & dosage
-
Receptors, Fc / therapeutic use
-
Recombinant Fusion Proteins / administration & dosage
-
Recombinant Fusion Proteins / therapeutic use
-
Temozolomide
-
Thrombopoietin / administration & dosage
-
Thrombopoietin / therapeutic use
-
Treatment Failure
Substances
-
Receptors, Fc
-
Recombinant Fusion Proteins
-
Dacarbazine
-
Thrombopoietin
-
romiplostim
-
Filgrastim
-
Temozolomide